Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK to support training of frontline health workers across Ghana, Kenya and Nigeria
GSK is to support the training of more than 9,000 health workers in Ghana, Kenya and Nigeria over the next three years.
-
GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD
GSK presented data on the role of blood eosinophils as a potential biomarker to determine responsiveness to treatment with ICS
-
GSK’s ECLIPSE study shows association between improving health status and reduced morbidity and mortality in patients with COPD
keeping stable health status in patients with COPD significantly reduces the likelihood of exacerbation, hospital admission and dying.
-
GSK responds to latest report from the O’Neill Review on antibiotic resistance
It is essential that we find new ways to increase antibiotics R&D and create a future pipeline of new treatments.
-
GSK and UNC-Chapel Hill announce novel partnership to accelerate search for HIV cure
Unique collaboration will create HIV Cure center and a new company to bring together academic and pharmaceutical research scientists
-
GlaxoSmithKline plc announces Board and Committee changes
GSK today announces that Manvinder Singh (Vindi) Banga will join GSK’s Board as a Non-Executive Director on 1 September 2015.
-
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.
-
Results announcement for the first quarter 2015
GSK reports Q1 sales of £5.6 billion; Core EPS of 17.3p (-16%) CER
-
GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID
Today announced the submission of a marketing application to the EMA for a gene therapy (GSK2696273) to treat patients with a rare disease
-
FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US
GSK and THRX announced approved once-daily treatment of asthma in patients aged 18+ BreoEllipta is not for the relief of acute bronchospasm.
-
GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2 which does not diminish in the age groups studied
Shingles is a significant public health burden, more than 90% of adults aged 50 years and over are at risk.
-
Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up
Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate published today in The Lancet.
-
GSK to establish global vaccines R&D centre in the US
New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint
-
GSK statement on meningitis vaccination in the UK
GSK reached an agreement with the UK’s Department of Health that will enable babies to receive its meningitis B vaccine through the NHS
-
GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD
Two further GSK products, Duac® Combination Gel and Synflorix™, also gain approval in Japan.
-
GSK’s 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US
GSK is encouraging scientists to submit their novel early drug discovery research proposals into its Discovery Fast Track Challenge
-
GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma
GSK and THRX announced the outcome of the joint meeting for a once-daily inhaled treatment for asthma in patients aged 12 years and older.
-
GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
GSK today announced the start of a phase III programme to evaluate the efficacy of retosiban, an investigational oxytocin antagonist.
-
GSK becomes partner in new global fund to accelerate dementia research
Company makes $25m (approx £17m) investment in first-of-its-kind venture capital fund focused on dementia
-
GSK transaction
Exclusively intended for persons who are not residents of the United States and who are not physically present in the United States.
